Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 18, 2021February 18, 2021

Eurordis Survey: Healthcare Experience Worse for Rare Disease Patients

News, syndicated

People with rare disorders have a worse healthcare experience than those affected by chronic diseases, according to the results of an international survey conducted by Eurordis-Rare Diseases Europe. Indeed, rare ... Read more

January 27, 2021January 27, 2021

Crysvita Effective at Easing Children’s Pain and Aiding Life Quality, Trial Shows

News

Switching from conventional therapy to Crysvita (burosumab) leads to clinically relevant reductions in pain and fatigue, and better quality of life, in children with X-linked hypophosphatemia (XLH) ages 5 to 12, ... Read more

January 20, 2021January 20, 2021

Multidisciplinary Approach Key for XLH, Experts Say in Webinar

News

A multidisciplinary approach based on pediatrics, orthopedics, and functional therapy specialties is crucial for managing and treating children and adults living with X-linked hypophosphatemia (XLH), experts emphasized on a recent ... Read more

November 26, 2020November 26, 2020

Survey Finds COVID-19 Disrupted Care, Well-Being of Rare Disease Patients in Europe

News, syndicated

The first wave of COVID-19 in Europe severely disrupted access to care and raised stress and anxiety in people with rare diseases, negatively affecting their health and well-being, according to a ... Read more

July 23, 2020July 23, 2020

Thorough Analyses Needed to Prevent Misdiagnosis of XLH Patients, Case Study Asserts

News

Complete clinical and genetic analyses are needed to correctly diagnose X-linked hypophosphatemia (XLH), according to the case study of a woman whose disease was misdiagnosed as osteoporosis for years. The case report, ... Read more

May 27, 2020May 27, 2020

Crysvita Treatment for Nearly 2 Years Continues to be Safe for XLH Patients, Trial Data Show

News

Treatment for nearly two years with Crysvita (burosumab) continued to maintain normal blood levels of phosphate and was found to be safe in adults with X-linked hypophosphatemia (XLH), according to ... Read more

May 13, 2020July 16, 2020

New Surgery Technique May Correct Severe Bowed Legs in XLH Patients, Case Study Shows

News

A new technique of osteotomy — a surgery in which bone is cut to allow repositioning — may be an effective approach to correct severe bowed legs in people with ... Read more

January 8, 2020January 8, 2020

Symptoms and Treatment Burden of XLH Changes Throughout Life, Study Reports

News

The burden of X-linked hypophosphatemia (XLH) is centered on treatment in childhood, expands to psychological impact and other factors in adolescence, and shifts in adulthood to the need for other ... Read more